# Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

> **NCT03514511** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 47 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** LEO 138559
- **DRUG:** LEO 138559 placebo

## Key facts

- **NCT ID:** NCT03514511
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-07
- **Primary completion:** 2021-03-02
- **Final completion:** 2021-03-02
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03514511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03514511, "Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03514511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*